本页面由Tiger Trade Technology Pte. Ltd.提供服务

Neoleukin Therapeutics, Inc.

3.49
0.0000
成交量:- -
成交额:39.34万
市值:3,279.87万
市盈率:-1.14
高:3.49
开:3.49
低:3.49
收:3.49
52周最高:4.70
52周最低:1.90
股本:939.79万
流通股本:544.90万
量比:- -
换手率:- -
股息:- -
股息率:- -
每股收益(TTM):-3.0649
每股收益(LYR):-5.2115
净资产收益率:-37.88%
总资产收益率:-18.70%
市净率:0.44
市盈率(LYR):-0.67

数据加载中...

2024/01/05

重要事件披露

Form 8-K - Current report
2023/12/28

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/12/22

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/22

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/12/21

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/12/19

重要事件披露

Form 8-K - Current report
2023/12/07

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2023/12/07

重要事件披露

Form 8-K - Current report
2023/12/04

重要事件披露

Form 8-K - Current report
2023/12/04

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2023/12/01

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2023/11/14

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/09

SEC问询函

Form CORRESP - Correspondence
2023/11/09

SEC问询函

Form CORRESP - Correspondence
2023/10/19

SEC问询函

Form CORRESP - Correspondence
2023/10/11

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/06

企业合并公告

Form 425 - Prospectuses and communications, business combinations
2023/09/29

SEC问询函

Form CORRESP - Correspondence
2023/09/22

重要事件披露

Form 8-K - Current report
2023/08/17

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]